Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Truist lowered the firm’s price target on Regeneron (REGN) to $1,137 from $1,200 and keeps a Buy rating on the shares after ...

The results are very encouraging news for Amgen and Repatha, which is in a head-to-head marketing battle with Sanofi and Regeneron’s Praluent to be the dominant PCSK9 inhibitor. Both drugs have ...

Regarding the OX40 target itself, Amgen’s view is that targeting the OX40 receptor is better and Sanofi believes that targeting the OX40 ligand is better. The two approaches were not ...

Analysts had predicted that the new drug class would be priced at around $10,000 a year, so the premium being sought by Amgen and Sanofi in the US will increase calls for measures to pare down the ...

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

Sanofi SNY announced that the FDA has approved the label expansion ... The SNY drug is also approved in combination with Amgen’s Kyprolis (carfilzomib) and dexamethasone for treating patients with ...

In the wake of the U.S. Supreme Court’s decision in Amgen Inc. v. Sanofi, 598 U.S. 594 (2023) (Amgen), in which the Court addressed whether Amgen’s functional antibody genus claims satisfy the ...

Bank of America Securities analyst Graham Parry maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target ...

Amgen (NASDAQ:AMGN) shares were down 5% Wednesday ... look competitive in AD” relative to other approved drugs such as Sanofi (SNY) and Regeneron’s (REGN) Dupixent and AbbVie’s (ABBV ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the National ... Morgan Stanley backs Overweight on Regeneron after Amgen temporarily enjoined Closing Bell Movers: Micron rallies ...

Recombinant Dna technology market is expected to reach USD 327.63 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.6% from 2024 to 2031. BURLINGAME, CA, UNITED STATES, October 8 ...